Multidimensional super-response to omalizumab in a patient with N-ERD: 9-year follow-up of a case report

Abstract

In recent years, biological therapy based on endotyping has become a therapeutic option for patients with type 2 inflammatory process with chronic rhinosinusitis with nasal polyps with or without bronchial asthma. It is also used in the course of a particularly aggressive chronic rhinosinusitis with nasal polyps in patients with bronchial asthma and hypersensitivity to non-steroidal anti-inflammatory drug (NSAID-exacerbated respiratory disease, N-ERD). Identification of the patient’s inflammatory endotype enables targeted biological treatment and optimal results from biological therapy. The search for biomarkers that identify patients who will benefit from biological treatment remains a current topic of investigation. A particularly difficult therapeutic decision concerns patients with a mixed endotype (eosinophilic/allergic), which affects patients with N-ERD. The authors present a case of multidimensional beneficial results in a 39-year-old female patient with N-ERD syndrome during biological treatment with omalizumab. The parameters of inflammation, the results of computed tomography, and the results of questionnaires assessing the patient’s quality of life before, after 4 months and 9 years of biological treatment are presented. Excellent results were found in all criteria of efficacy of biological treatment: reduced nasal polyp size (complete remission of polyps in the paranasal sinuses), reduced need for systemic corticosteroids (no systemic steroids have been used since the start of therapy), improved sense of smell, reduced impact of comorbidities (complete control of bronchial asthma) and in the patient’s opinion, an extremely significant improvement in quality of life. Thus, the patient can be considered as a super-responder. Analysis of the parameters of patients who achieved optimal therapeutic results may also be helpful in selecting type of biological treatment for future patients.

Keywords

CRSwNP / omalizumab / N-ERD / super-responder / case report

References

[1] The WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995; 41: 1403-9.

[2] Delpierre C, Lefèvre T. Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol. 2023; 8: 1112159.

[3] Kariyawasam HH, Chandrasekharan DP, Jacques T, Stokes P, Dziadzio M, Gane SB, et al. Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Rhinology. 2023; 61: 98-107.

[4] Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58: 1-464.

[5] Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019; 7: 2812-20.e3.

[6] Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023; 61: 194-202.

[7] Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015; 135: 676-81.e1.

[8] van der Lans RJL, Fokkens WJ, Reitsma S. Therapeutic Options for Chronic Rhinosinusitis in N-ERD Patients. Front Allergy. 2021; 2: 734000.

[9] Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy. 2019; 74: 28-39.

[10] Portal Gov.pl [Internet]. [cited 2025 Sep 25]. Available from: https://www.gov.pl/attachment/0ca7e3df-f174-41ba-9930-3c0260a704aa

[11] Highlights of prescribing information [Internet]. [cited 2025 Sep 25]. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf

[12] Whitworth L, Kimsey-House H, Kimsey-House K, Sandahl P. Co-Active Coaching: New Skills for Coaching People Toward Success in Work and Life (2nd ed.). Davies-Black Publishing; 2007.

[13] Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017; 5: 1061-70.e3.

[14] Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. Laryngoscope. 2011; 121: 2684-701.

[15] Van Broeck D, Steelant B, Scadding G, Hellings PW. Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)? Front Allergy. 2023; 4: 1080951.

[16] Forster-Ruhrmann U, Stergioudi D, Pierchalla G, Fluhr JW, Bergmann KC, Olze H. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology. 2020; 58: 226-32.

[17] Tepetam FM, Özden Ş, Kılıç FK, Örçen C, Yakut T. Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD. World Allergy Organ J. 2023; 16: 100817.

[18] Quint T, Dahm V, Ramazanova D, Arnoldner MA, Kurz H, Janik S, et al. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization. J Allergy Clin Immunol Pract. 2022; 10: 506-16.e6.

[19] Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB ; Delphi Panel. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. J Allergy Clin Immunol Pract. 2021; 9: 3997-4004.